Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8062667 | NEXTWAVE | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(5 years from now) | |
US8778390 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) | |
US8956649 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) | |
US8465765 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) | |
US9040083 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) | |
US8287903 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) | |
US8563033 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 September, 2012
Treatment: Treatment of a patient by administering the formulation recited in claim 1 or claim 23; Method of treating attention deficit hyperactivity disorder by administering the composition of claim 1; Treatin...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic